Jupiter Neurosciences Files 8-K: Material Agreement

Ticker: JUNS · Form: 8-K · Filed: 2024-12-04T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, disclosure, exhibits

TL;DR

JUPITER NEUROSCIENCES SIGNED A BIG DEAL - FILING 8-K

AI Summary

On December 2, 2024, Jupiter Neurosciences, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and exhibits. The exact nature of the agreement and the details of the disclosures and exhibits are not specified in this filing summary.

Why It Matters

This filing indicates a significant event for Jupiter Neurosciences, Inc., potentially involving a new contract, partnership, or financial transaction that could impact its business operations and future prospects.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on its terms, introducing a degree of uncertainty.

Key Players & Entities

FAQ

What is the specific nature of the material definitive agreement entered into by Jupiter Neurosciences, Inc. on December 2, 2024?

The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 2, 2024.

What information is provided in the Regulation FD disclosure mentioned in the filing?

The filing states that a Regulation FD Disclosure was made, but the specific content of this disclosure is not detailed in the provided summary.

What types of financial statements and exhibits are included with this 8-K filing?

The filing indicates that Financial Statements and Exhibits are included, but their specific content is not detailed in the provided summary.

When was Jupiter Neurosciences, Inc. incorporated, and in which state?

Jupiter Neurosciences, Inc. was incorporated in Delaware.

What is the principal executive office address and phone number for Jupiter Neurosciences, Inc.?

The principal executive office is located at 1001 North US HWY 1, Suite 504, Jupiter, Florida 33477, and the phone number is (561) 406-6154.

From the Filing

0001493152-24-048687.txt : 20241204 0001493152-24-048687.hdr.sgml : 20241204 20241204165734 ACCESSION NUMBER: 0001493152-24-048687 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20241202 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241204 DATE AS OF CHANGE: 20241204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 241526882 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm false 0001679628 0001679628 2024-12-02 2024-12-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): December 2, 2024   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   001-41265   47-4828381 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification Number)   1001 North US HWY 1 , Suite 504 Jupiter , Florida 33477 (Address of principal executive offices)   (561) 406-6154 (Registrant’s telephone number, including area code)       (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐             Item 1.01 Entry into a Material Definitive Agreement.   On December 2, 2024, Jupiter Neurosciences, Inc. (the “Company” or “us” or “we”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Dominari Securities LLC, as representative of the underwriters named on Schedule I thereto, relating to the Company’s firm commitment underwritten initial public offering (the “Offering”) of comm

View on Read The Filing